evipedia.ai
← Back

Bromantane for Health & Longevity

Evidence Review created on 11/04/2026 using AI4L / Opus 5.5

Also known as: Bromantan, Bromontan, Ladasten, Adamantylbromphenylamine, ADK-709, N-(2-adamantyl)-N-(4-bromophenyl)amine, N-(4-bromophenyl)adamantan-2-amine

Motivation

Bromantane, sold in Russia as Ladasten, is a synthetic compound built on the same cage-shaped core as the older drugs amantadine and memantine. It was created in the Soviet Union to help soldiers and athletes keep working through heat, low oxygen and exhaustion, and it later became a Russian prescription medicine for lasting tiredness. Its main proposed action is to switch on the brain’s own production of dopamine rather than to force a sudden release.

Interest outside Russia grew after several athletes tested positive for it at the 1996 Olympic Games, which led to a ban in sport the following year. Since then it has been sold online as a “smart drug” and promoted as a gentler alternative to classic stimulants. Most of its laboratory and clinical research appeared in Russian journals, much of it from groups linked to the institute that developed it.

This review examines what human and animal studies show about bromantane’s effects on tiredness, anxiety and mental performance, its side effects and drug interactions, how it is dosed and sourced, and whether any of this bears on long-term health for adults invested in their longevity.

Benefits - Risks - Protocol - Conclusion

This section lists overview articles and in-depth papers that discuss bromantane directly.

Only four items are listed: other web content on bromantane consists mainly of vendor pages, encyclopedias, forum threads and summaries without sources. No relevant content on bromantane was found from Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension Magazine or Lifespan.io; web searches and on-site searches of each platform returned no article, episode or post discussing it.

Grokipedia

  • Bromantane

    A long AI-written article covering chemistry, pharmacokinetics, Soviet development, the 1996 Olympic doping cases and the Russian trials; useful as a broad orientation, though several clinical details are unsourced.

Examine

No Examine article on bromantane exists. Examine.com does not typically cover prescription medications, and bromantane is certified as a drug in Russia (narrative review Oliynyk 2012), with an official 2012 label (RLS Ladasten label).

ConsumerLab

No ConsumerLab article on bromantane exists. ConsumerLab does not typically cover prescription medications, and bromantane is certified as a drug in Russia (narrative review Oliynyk 2012), with an official 2012 label (RLS Ladasten label).

Systematic Reviews

No systematic reviews or meta-analyses for Bromantane were found on PubMed as of 11/04/2026.

Neither the claimed anti-fatigue effect nor the principal risks (overstimulation, sleep disruption, long-term safety) is represented by a systematic review or meta-analysis.

Mechanism of Action

Bromantane is an adamantane derivative (built on a rigid, cage-shaped hydrocarbon scaffold). Its best-supported action, shown in rats, is indirect: a single dose raises gene activity of tyrosine hydroxylase (TH, the rate-limiting enzyme that turns tyrosine into the dopamine precursor L-DOPA) and DOPA decarboxylase (the enzyme that turns L-DOPA into dopamine), increasing new dopamine synthesis in the hypothalamus and striatum after an early phase of increased release (Vakhitova 2004; Mikhaylova 2007). A proposed upstream step is removal of silencing methyl tags from the TH gene promoter (Vakhitova 2006). In rats it also raises gene expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), proteins that support neuron survival and growth (Salimgareeva 2012).

A competing explanation, in the Russian label, credits increased dopamine release, blocked dopamine reuptake and modulation of the GABA-benzodiazepine receptor (GABA being the brain’s main calming messenger; benzodiazepines are sedatives acting there) (allmed.pro Ladasten monograph). In rat tissue, however, reuptake blocking needs micromolar concentrations (half-maximal at 3.56 micromolar), likely above clinical levels, with no direct effect on tested dopamine or serotonin receptors (Zimin 2010).

Pharmacokinetics: oral bioavailability is 42%; peak blood levels arrive at 2.75 hours in women and 4.0 hours in men; it is highly fat-soluble, stored in brain lipids and fat; liver hydroxylation is the main metabolic route, and it induces cytochrome P450 (CYP450, the liver’s drug-metabolizing enzymes; specific enzymes not named); urinary metabolites persist for two weeks (narrative review Oliynyk 2012). The label gives a half-life of 11.21 hours (allmed.pro Ladasten monograph).

Historical Context & Evolution

Bromantane came out of Soviet research on “actoprotectors”, drugs meant to raise physical work capacity under hypoxia (low oxygen), heat and exhaustion without raising oxygen use or heat production (narrative review Oliynyk 2012); its early animal studies were run at the Institute of Pharmacology in Moscow, now the Zakusov Institute (Morozov 1998). Soviet and Russian forces used it to speed recovery after heavy exertion; after 1991 it was used mainly in sports medicine.

After athletes tested positive for it at the 1996 Atlanta Olympics, a 1997 Lancet letter described it as a new doping agent (Burnat 1997). Anti-doping rules have prohibited it since 1997 (narrative review Oliynyk 2012), and the World Anti-Doping Agency still lists it among stimulants (WADA Prohibited List).

In the 2000s it was repositioned as Ladasten for asthenia (persistent physical and mental exhaustion) and neurasthenia (a fatigue disorder with irritability, poor concentration and poor sleep). After a pilot trial (Siuniakov 2006), a randomized trial found faster and greater symptom relief than placebo (Neznamov 2009); both came from the developer’s Zakusov Institute, a conflict of interest. An uncontrolled 728-patient study followed (Voznesenskaia 2010; sponsor not stated), and the 2012 label, reproduced by the Russian drug register RLS, set 2–4 week courses (RLS Ladasten label).

It reached Western “smart drug” markets through online vendors, not new trials, and European and Australian medicines control laboratories report it among unauthorized products (Vanhee 2025). Its use has changed more than its evidence: no independent Western trial has re-tested the Russian findings.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: the fatigue evidence is one developer-group placebo-controlled trial, an open-label trial without a between-group test and an uncontrolled study.

Medium 🟩 🟩

Reduced Asthenia and Fatigue Symptoms

Bromantane reduced core fatigue symptoms in people with asthenia or neurasthenia, its approved Russian indication. A randomized placebo-controlled trial from the developer’s Zakusov Institute group (Neznamov) found faster and larger symptom reduction than placebo (Neznamov 2009); an open randomized trial from an independent Perm group (Sumlivaya) reported larger fatigue-score drops than in untreated patients, without a between-group test, after tick-borne encephalitis (a viral brain infection) (Sumlivaya 2013). An uncontrolled 728-patient study reported onset by day 3 (Voznesenskaia 2010). All data are short-term, in fatigued patients.

Magnitude: Visual analogue fatigue scores (a self-rating marked on a line) fell 2.5-fold with bromantane and 1.4-fold without it, not compared between groups (Sumlivaya 2013); 76.0% of 728 patients met the CGI-S (Clinical Global Impression–Severity, a clinician rating) responder criterion (no control group) (Voznesenskaia 2010).

Reduced Anxiety Alongside Fatigue

Unlike classic stimulants, bromantane combined an activating effect with an anxiety-reducing one. The placebo-controlled neurasthenia trial described both actions (Neznamov 2009), and in the Perm trial scores on the STAI (State-Trait Anxiety Inventory, a validated anxiety questionnaire) fell within the bromantane group (Sumlivaya 2013). EEG (electroencephalogram, a recording of brain electrical activity) data suggest the anxiety-reducing pattern dominates in patients with weak baseline alpha rhythm (Neznamov 2008). Only the developer group’s trial compared anxiety against placebo.

Magnitude: Direction only: anxiety scores fell with bromantane in patients with fatigue disorders, most clearly in those with weak baseline alpha rhythm; the literature available in English reports no between-group outcome figure.

Low 🟩

Mental Performance Under Fatigue ⚠️ Conflicted

In healthy volunteers, a single 100 mg dose improved psychophysiological test performance during mental fatigue, most in stress-prone people (Bogdan 2009). A placebo-compared study in 10 rested men found no change in mood or main performance measures (Viatleva 2000). Net: any benefit appears limited to fatigued states.

Magnitude: Direction only: improvement appeared in mentally fatigued, stress-labile volunteers and not in rested men; the literature reports no outcome figure.

Physical Endurance and Altitude Adaptation

Rodents showed greater endurance in treadmill and swim tests (Morozov 1998). Human data are indirect: bromantane 100 mg was tested only combined with bemitil (another actoprotector) during ascent to 3,750 m, where exercise tolerance improved (Kundashev 2014).

Magnitude: Direction only: better tolerance of physical activity at high altitude with the combination than with hypoxen (an antihypoxic drug) alone; the literature reports no outcome figure.

Speculative 🟨

Neuroplasticity and Neurotrophic Support

In rats, bromantane raised BDNF and NGF gene expression (Salimgareeva 2012) and turned short-term into long-lasting synaptic strengthening (Mikhaylova 2007). Basis is mechanistic only; no human study measured brain aging or lifespan.

Anti-Inflammatory and Antidepressant-Like Effects

In mice given an inflammation-provoking bacterial toxin, bromantane lowered TNF-α and IL-6 (inflammatory signaling proteins) more than the antidepressant imipramine and prevented depression-like behavior (Tallerova 2011). Basis is animal data.

Benefit-Modifying Factors

  • Genetic polymorphisms: No pharmacogenetic study exists. Variants in dopamine-handling genes such as COMT (catechol-O-methyltransferase, an enzyme that breaks down dopamine) could plausibly shift response, but this is untested.
  • Baseline brain activity (EEG alpha rhythm): Strong-alpha patients showed mainly stimulant effects and weak-alpha patients mainly anxiety-reducing effects (Neznamov 2008); weak-alpha patients also rated both drug and placebo more favorably (Neznamov 2012).
  • Baseline fatigue and stress reactivity: Effects were clearer in fatigued or stress-labile people than in rested ones (Bogdan 2009; Viatleva 2000); actoprotector theory predicts little effect in people with high baseline resilience (narrative review Oliynyk 2012).
  • Sex: Absorption is faster in women, with peak blood levels at 2.75 hours versus 4.0 hours in men (narrative review Oliynyk 2012); no sex-specific efficacy data exist.
  • Pre-existing conditions: Evidence centers on asthenia, neurasthenia and post-infection fatigue. Small Russian studies also explored Parkinson’s disease non-motor symptoms (Sarycheva 2011, no abstract), irritable bowel syndrome (Uspenskiĭ 2010) and cancer fatigue within a three-drug regimen (Ryazankina 2015).
  • Age: The label excludes people under 18 (allmed.pro Ladasten monograph); the English abstracts report no results for adults over 65, so benefit at the older end of the target range is unknown.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: adverse-event data come from one placebo-controlled trial and uncontrolled studies that report no event rates against a comparison group.

Medium 🟥 🟥

No risk reaches Medium: no trial reports an adverse-event rate against a placebo or comparison group, and the remaining signals are animal toxicology.

Low 🟥

Overstimulation and Difficulty Falling Asleep ⚠️ Conflicted

The label lists excess activation and sleep-onset problems, managed by lowering the dose (allmed.pro Ladasten monograph). In the multicenter study 3% reported adverse events (Voznesenskaia 2010), while neurasthenia patients given single 15 mg test doses rated tolerability comparable to placebo (Reutova 2011). Net: mild and uncommon at label doses.

Magnitude: 3% of 728 patients reported any adverse event and 0.8% stopped treatment; the study had no placebo or comparison group (no control group) (Voznesenskaia 2010).

Allergic Reactions

The label lists hypersensitivity reactions in susceptible people and contraindicates use after prior hypersensitivity (allmed.pro Ladasten monograph). No serious adverse event of any kind was reported among 728 patients (Voznesenskaia 2010).

Magnitude: Not quantified in available studies. The label lists allergic reactions without a frequency, and no trial abstract reports a case.

Tolerance, Dependence and Withdrawal ⚠️ Conflicted

As a dopamine-enhancing drug, bromantane carries a theoretical tolerance and dependence risk; users report tolerance after six weeks of daily use (Outliyr Bromantane report). The placebo-controlled trial found no withdrawal syndrome in a one-week placebo phase after 28 days (Neznamov 2009). Net: no signal within four weeks.

Magnitude: Not quantified in available studies. The trial reported withdrawal as absent without giving rates, and tolerance reports are anecdotal.

Speculative 🟨

Blood Cell and Liver Changes at High Doses

In rats given 150–600 mg/kg for months, red cells, hemoglobin and white cells rose and then fell, with reversible agranulocytosis (loss of infection-fighting white cells) and enlarged liver cells (Bugaeva 1999). Basis is animal data.

Reproductive and Developmental Effects

In rats, maternal dosing altered litter size and offspring weight and behavior (Iezhitsa 2001); sperm effects were inconsistent (Khamidova 2000; Khamidova 2005). Basis is animal data only.

Neurological Toxicity at High Doses

In rats, single doses above 600 mg/kg suppressed activity, and anticholinergic effects (blocked acetylcholine signaling) appeared from 30 mg/kg (Iezhitsa 2002). The label notes overdose sedation (allmed.pro Ladasten monograph). Animal and label data only.

Risk-Modifying Factors

  • Genetic polymorphisms: No pharmacogenetic data exist. The liver enzymes that metabolize bromantane are unidentified, so no metabolizer genotype can be flagged; dopamine-pathway variants such as COMT are untested.
  • Baseline biomarkers: Elevated blood pressure or resting heart rate are logical caution flags for an activating drug. In anesthetized rats bromantane raised cardiac output, lowered heart rate, caused only a brief insignificant blood pressure rise and weakly enhanced adrenaline’s blood-pressure-raising effect (Morozov 2000).
  • Sex: Women who could become pregnant face the pregnancy contraindication (allmed.pro Ladasten monograph); faster absorption in women (narrative review Oliynyk 2012) brings earlier peak levels.
  • Pre-existing conditions: Insomnia, agitated anxiety, bipolar disorder, psychosis and a history of stimulant misuse may worsen with dopamine activation (inferred; no human data). Liver disease may slow clearance, given hepatic metabolism (narrative review Oliynyk 2012).
  • Age: Use under 18 is contraindicated (allmed.pro Ladasten monograph). Sensitivity of older adults to activation and sleep disruption is untested.

Key Interactions & Contraindications

Documented interactions:

  • Thiopental (a barbiturate, an older sedative-anesthetic drug class): The label states bromantane reduces thiopental’s sleep-inducing action (allmed.pro Ladasten monograph), consistent with liver-enzyme induction (narrative review Oliynyk 2012). Consequence: weaker anesthesia or sedation. Mitigation: disclosure of use before any procedure.
  • Benzodiazepines (sedative anti-anxiety drugs: diazepam, alprazolam): The label states bromantane does not weaken their anxiety-reducing effect (allmed.pro Ladasten monograph); a review reports it counters tranquilizer sedation (narrative review Oliynyk 2012). Consequence: anxiety relief preserved, sedation possibly weaker. Mitigation: disclosure of use before procedural sedation.

Theoretical interactions (inferred from mechanism, not studied in humans):

  • MAO inhibitors (selegiline, phenelzine, tranylcypromine): Inferred from increased dopamine synthesis plus blocked breakdown by MAO (monoamine oxidase, the enzyme that degrades dopamine). Consequence: agitation or a hypertensive reaction. Avoid.
  • Prescription stimulants (amphetamine, methylphenidate, modafinil): Inferred from additive dopaminergic stimulation. Consequence: insomnia, anxiety, raised heart rate. Mitigation: no same-day use.
  • Dopaminergic drugs (levodopa, pramipexole, bupropion): Inferred from additive dopamine effects. Consequence: agitation, nausea or impulse-control symptoms. Mitigation: prescriber-coordinated dose adjustment.
  • Dopamine blockers (haloperidol, risperidone, metoclopramide): Inferred from opposing dopamine actions; bromantane countered neuroleptic (antipsychotic) effects in rats (Morozov 1999). Consequence: reduced efficacy of either drug. Mitigation: prescriber review before combining.
  • Drugs cleared by liver enzymes (warfarin, oral contraceptives, phenobarbital): Inferred from reported CYP450 induction (narrative review Oliynyk 2012). Consequence: lower drug levels, weaker anticoagulation or contraceptive failure. Mitigation: INR (blood-clotting test) checks; backup contraception.
  • Over-the-counter sleep aids (diphenhydramine, doxylamine): Inferred from opposing effects on arousal, plus additive anticholinergic action seen in high-dose rat studies (Iezhitsa 2002). Consequence: weaker sleep aid effect. Mitigation: morning-only bromantane dosing.
  • Over-the-counter decongestants and caffeine (pseudoephedrine, phenylephrine, caffeine): Inferred from additive stimulation; in rats bromantane weakly enhanced adrenaline’s blood-pressure effect (Morozov 2000). Consequence: insomnia, palpitations, raised blood pressure. Mitigation: limited caffeine and no decongestants during courses.
  • Dopamine-precursor and stimulant supplements (L-Tyrosine, Mucuna pruriens, yohimbine, synephrine): Inferred from additive dopaminergic and adrenergic (adrenaline-like) stimulation. Consequence: overstimulation and raised blood pressure. Mitigation: no combined use with bromantane during courses.
  • Adaptogenic supplements (plant extracts promoted to raise resistance to stress; Rhodiola rosea, Panax ginseng): Inferred from additive activating effects. Consequence: overstimulation or sleep disruption. Mitigation: introduction of one agent at a time.
  • Alcohol: Inferred from opposing effects on alertness. Consequence: subjective masking of intoxication. Mitigation: no alcohol around dosing.

Populations who should avoid Bromantane:

  • Pregnancy: Contraindicated by the label (allmed.pro Ladasten monograph); rat studies show offspring effects (Iezhitsa 2001).
  • Breastfeeding: Contraindicated by the label (allmed.pro Ladasten monograph).
  • Under 18 years: Contraindicated by the label (allmed.pro Ladasten monograph).
  • Prior hypersensitivity to bromantane or tablet components: Contraindicated by the label (allmed.pro Ladasten monograph).
  • Athletes subject to anti-doping testing: Prohibited as a stimulant (WADA Prohibited List); urinary metabolites remain detectable for two weeks (narrative review Oliynyk 2012).
  • Bipolar disorder or psychotic disorders: Inferred from dopaminergic activation, which can trigger mania or psychosis; no human data.
  • History of stimulant use disorder: Inferred from dopaminergic reward-pathway activation; no human data.
  • Severe liver impairment (Child-Pugh Class C, the most severe liver-function class): Inferred from hepatic metabolism (narrative review Oliynyk 2012); no human data.

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Morning-only dosing: Taking the last dose before 4 p.m., as the label specifies (RLS Ladasten label), limits sleep-onset problems given the 11.21-hour half-life (allmed.pro Ladasten monograph).
  • Lowest effective dose: Starting at the label’s lowest single dose of 50 mg (RLS Ladasten label) and lowering the dose if overactivation appears, which the label advises instead of stopping (allmed.pro Ladasten monograph), mitigates overstimulation.
  • Time-limited courses: Courses of 2–4 weeks (RLS Ladasten label) followed by breaks of at least equal length limit tolerance and the unknown effects of long-term use.
  • Pregnancy exclusion: A negative pregnancy test before each course plus barrier contraception (given possible enzyme induction of hormonal methods) prevents fetal exposure, a risk suggested by rat studies (Iezhitsa 2001).
  • Stimulant separation: No same-day use with prescription stimulants or MAO inhibitors, and caffeine kept under 200 mg daily, prevents additive overstimulation and blood pressure rises.
  • Blood pressure and heart rate checks: Week-1 home readings, stopping at 140/90 mmHg (stage 2 hypertension in a cardiology-society guideline whose members earn revenue treating hypertension; Whelton 2018) or resting heart rate over 100 beats/minute, limit label-listed overstimulation.
  • Blood and liver checks: Blood count and ALT (alanine aminotransferase, a liver enzyme) around courses over 4 weeks; stopping if neutrophils (infection-fighting white cells) fall below 1.5 × 10⁹/L or ALT exceeds 3 times normal prevents blood and liver harm.
  • Verified sourcing: Products with independent HPLC (high-performance liquid chromatography, a purity test) or mass-spectrometry identity testing mitigate mislabeling and contamination found in illicit nootropic (cognition-enhancing drug) markets (Vanhee 2025).
  • Anti-doping avoidance: Tested athletes avoiding bromantane entirely prevents sanctions, since metabolites persist about two weeks (narrative review Oliynyk 2012).
  • Pre-procedure disclosure: Informing the anesthetist before surgery prevents unexpectedly weak barbiturate anesthesia (allmed.pro Ladasten monograph).

Therapeutic Protocol

Other parameters without a citation (e.g., timing, cycling, titration steps) reflect common practice.

  • Label regimen (conventional approach): 50–100 mg per dose and 100–200 mg daily in two doses, with or without food, for 2–4 weeks in asthenia and neurasthenia (RLS Ladasten label).
  • Trial regimens: 50–100 mg daily for 28 days (Voznesenskaia 2010); 100 mg daily for 25 days (Sumlivaya 2013); single 100 mg doses in healthy volunteers (Bogdan 2009).
  • Biohacker low-dose approach: Nick Urban of Outliyr reports 30 mg in the morning, taken intermittently rather than daily (Outliyr Bromantane report); this is personal practice, not trial-tested.
  • Time of day: Morning or early afternoon; the label excludes doses after 4 p.m. (RLS Ladasten label). Peak blood levels arrive 2–4 hours after a dose (allmed.pro Ladasten monograph).
  • Half-life: About 11.21 hours (allmed.pro Ladasten monograph), so effects span most of the waking day and steady levels build over 2–3 days of regular dosing.
  • Single versus split dose: The label splits daily doses of 100–200 mg into two intakes (RLS Ladasten label); low-dose users take a single 30 mg morning dose (Outliyr Bromantane report).
  • Genetic polymorphisms: No variant is known to change dosing; the metabolizing liver enzymes are unidentified, so no genotype-guided adjustment exists.
  • Sex: Women absorb bromantane faster than men (narrative review Oliynyk 2012); the label sets no sex-specific dose.
  • Age: Not for use under 18 (allmed.pro Ladasten monograph); no older-adult data exist, so adults over 65 commonly start at the label’s lowest single dose of 50 mg (RLS Ladasten label).
  • Baseline biomarkers: Baseline EEG alpha type predicted a stimulant versus anxiety-reducing profile (Neznamov 2008); elevated baseline blood pressure argues for the lowest dose.
  • Pre-existing conditions: Trials in fatigue disorders used 50–100 mg daily (Voznesenskaia 2010); people prone to insomnia or anxiety commonly start at the label’s lowest single dose of 50 mg (RLS Ladasten label).

Discontinuation & Cycling

  • Short-term by design: Label courses last 2–4 weeks (RLS Ladasten label); no study has examined continuous or lifelong use.
  • Withdrawal effects: No withdrawal syndrome appeared when bromantane was switched to placebo after 28 days (Neznamov 2009).
  • Tapering: No tapering protocol has been published; trials stopped bromantane abruptly without reported problems (Neznamov 2009).
  • Persistence after stopping: The anti-fatigue effect persisted one month after the course ended (Voznesenskaia 2010).
  • Cycling: A community pattern of 4 weeks on and 4–8 weeks off is described (Outliyr Bromantane report); no trial has tested whether cycling preserves efficacy.

Sourcing and Quality

  • Pharmaceutical form: Ladasten 50 mg and 100 mg tablets were made by Lekko in Russia (RLS Ladasten label); a Russian drug reference now lists the product as discontinued (allmed.pro Ladasten monograph).
  • Gray-market products: Outside Russia, bromantane is sold as “research chemical” powder or capsules; official medicines control laboratories in Europe and Australia found it among illicit nootropic products (Vanhee 2025).
  • What to look for: A batch-matched certificate of analysis from an independent laboratory confirming identity by HPLC or mass spectrometry and purity of at least 98%, with no undisclosed stimulants.
  • Reputable brands: No brand can be named as reputable: no Western pharmaceutical-grade or third-party-certified (e.g., by NSF International or the United States Pharmacopeia) bromantane product exists.
  • Formulation: Bromantane is highly fat-soluble (narrative review Oliynyk 2012); capsules or tablets give more accurate dosing than home-measured powder.

Practical Considerations

  • Time to effect: Single-dose effects on mental performance appear within hours (Bogdan 2009); the anti-fatigue effect in patients appeared by day 3 of a course (Voznesenskaia 2010).
  • Common pitfalls: Dosing in the evening, combining with other stimulants, inaccurate powder measurement, extending courses beyond 4 weeks without monitoring, and expecting longevity benefits that no study has measured.
  • Regulatory status: Registered in Russia under a 2012 label (RLS Ladasten label) and dispensed by prescription, now discontinued (allmed.pro Ladasten monograph); unauthorized in the European Union and Australia (Vanhee 2025); prohibited in sport (WADA Prohibited List).
  • Cost and accessibility: Gray-market courses cost about $40–100 per 30 days (Outliyr Bromantane report); legal access outside Russia is generally unavailable.
  • Evidence provenance: Nearly all human data come from Russian groups, several tied to the developer’s institute; most papers are in Russian with English abstracts only.

Interaction with Foundational Habits

  • Sleep: Direction: blunting when taken late (label-listed sleep-onset problems) but reportedly normalizing the sleep–wake cycle in fatigued patients (Voznesenskaia 2010). Mechanism: dopaminergic arousal with an 11-hour half-life. Practical: last dose before 4 p.m.; time to fall asleep is the marker to track.
  • Nutrition: Direction: none documented. The label allows dosing with or without food (RLS Ladasten label); the drug is fat-soluble and stored in fat tissue (narrative review Oliynyk 2012). Practical: no diet has been tested; high-dose tyrosine or Mucuna pruriens add dopamine load.
  • Exercise: Direction: potentiating in rodents (greater endurance) (Morozov 1998); human data exist only in combination with bemitil at altitude (Kundashev 2014). Mechanism: psychostimulant plus membrane-protective effects on heart and skeletal-muscle mitochondria in rats (Morozov 1998). Practical: no data on training adaptation; tested athletes face sanctions.
  • Stress management: Direction: potentiating; stress-labile volunteers responded more (Bogdan 2009), and in stressed mice it normalized reduced benzodiazepine-receptor binding (Iarkova 2011). Practical: cortisol effects in humans are untested.

Monitoring Protocol & Defining Success

Baseline testing before a first course establishes reference values for the safety checks and for outcomes bromantane is expected to change: seated blood pressure and resting heart rate, a complete blood count, ALT, a validated fatigue questionnaire such as the MFI-20 (Multidimensional Fatigue Inventory), an anxiety questionnaire such as the STAI and, for women who could become pregnant, a pregnancy test.

Ongoing monitoring follows this cadence: home blood pressure and heart rate at 1 week and 2 weeks into each course, fatigue and anxiety scores at 2 and 4 weeks, and blood count and ALT at the end of any course longer than 4 weeks, then every 6–12 months for repeated courses. Success is a clear fall in fatigue scores from baseline without sleep disruption or blood pressure rise.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Blood pressure Below 130/80 mmHg (2017 ACC/AHA guideline target) Safety check: a rise stops or changes use ACC/AHA: American College of Cardiology/American Heart Association, professional bodies whose clinician members earn revenue treating hypertension; guideline target from Whelton 2018; conventional reference range 90/60–120/80 mmHg; seated, after 5 minutes’ rest, 2–4 hours after a dose
Resting heart rate 60–100 beats per minute (standard reference range) Safety check: a sustained rise stops or changes use Measure on waking and at peak blood levels 2–4 hours after a dose
MFI-20 fatigue score No established target; track change from the individual’s own baseline Expected to change: fatigue Self-rated questionnaire used in bromantane trials; repeat at the same time of day
STAI anxiety score No established target; track change from the individual’s own baseline Expected to change: anxiety Separate state and trait scores; state score responds to recent events
Complete blood count (neutrophils, hemoglobin) Neutrophils 1.5–8.0 × 10⁹/L; hemoglobin 12.0–15.5 g/dL in women, 13.5–17.5 g/dL in men (standard reference range) Safety check: a fall stops use Rat studies at high doses showed blood cell changes (Bugaeva 1999); no fasting needed
ALT 7–56 U/L (standard reference range) Safety check: a rise above 3 times normal stops use Liver metabolizes bromantane; enlarged liver cells in high-dose rat studies (Bugaeva 1999); pair with AST (aspartate aminotransferase, a second enzyme that leaks from damaged liver cells); avoid hard exercise 48 hours before
Pregnancy test (hCG) Negative (standard reference range) Safety check: a positive result stops use Before each course in women who could become pregnant; hCG is human chorionic gonadotropin

Qualitative markers:

  • Daytime energy and resistance to mental fatigue
  • Time to fall asleep and night waking
  • Calmness versus irritability or restlessness
  • Motivation and ability to sustain focused work
  • Exercise tolerance and recovery
  • Palpitations or headaches during a course
  • Mood and energy in the weeks after a course ends

Emerging Research

  • No registered trials: ClinicalTrials.gov lists no study of bromantane, Ladasten or bromantan, ongoing or completed (no NCT ID exists). A future placebo-controlled trial in healthy adults could extend relevance beyond fatigue disorders if positive, or confine it to clinical asthenia if null.
  • Independent replication: The placebo-controlled evidence comes from the developer’s institute (Neznamov 2009). An independent trial with published effect sizes would either support the current fatigue grade or weaken it.
  • Neurotrophic and anti-inflammatory signals: Rodent increases in BDNF and NGF (Salimgareeva 2012) and reductions in inflammatory signals (Tallerova 2011) could strengthen a brain-health case if reproduced in humans with biomarker endpoints.
  • T-cell effects: Bromantane corrected stress-related shifts in T-lymphocyte subsets in mice (Tallerova 2014); human immune measurements could strengthen or weaken the claimed immune-modulating effect.
  • Long-term safety gap: No human data extend beyond 28 days, and chronic high-dose rat studies showed blood changes (Bugaeva 1999); longer human safety data could weaken or reassure on the risk side.
  • Illicit market quality: Surveillance by official medicines control laboratories found bromantane among illicit nootropic products (Vanhee 2025); further product testing could weaken the practical case if identity or dose prove unreliable.

Conclusion

Bromantane is a Russian-developed drug that prompts the brain to make more of its own dopamine, and in Russia it has been prescribed in short courses for persistent exhaustion. For adults seeking more energy and resilience over the long term, the strongest evidence is narrow. Small Russian studies in people with fatigue disorders found less tiredness, often with calmer mood rather than the restlessness of classic stimulants, and the effect appeared within days. In healthy people, benefits appeared only in states of fatigue, and claims of better physical endurance rest mostly on animal work and on one study that paired it with another drug. Brain-protective and anti-inflammatory effects have been seen only in rodents, and nothing links bromantane to slower aging or longer life.

Reported side effects at standard doses were uncommon and mild, chiefly overstimulation and trouble falling asleep, with no withdrawal after four weeks. Safety beyond a month is unknown, high doses in animals affected blood cells and offspring, and the drug is barred in tested sport and unauthorized in Europe and Australia, so most supply outside Russia is unregulated.

The evidence base is small, short and almost entirely Russian, and several key studies came from the institute that developed the drug, a conflict of interest that limits confidence in the positive findings. Taken together, bromantane is a plausible short-term anti-fatigue option with a modest known risk profile, not an established longevity intervention.

Top - Benefits - Risks - Protocol